Efficacy and safety of 0.1 % brimonidine as a starting monotherapy and when added to combination therapy of glaucoma

Purpose : to analyze the efficacy and safety of Santabrim® as a starting monotherapy and when added to combination therapy for glaucoma. Material and methods . The study was conducted on 60 patients (60 eyes), including 21 (35 %) men and 39 (65 %) women, with initial or advanced primary open-angle glaucoma with moderately elevated IOP. The average age of patients was 63.4 years. The first group (30 eyes) consisted of patients who were prescribed Santabrim® 2 times a day as a starting monotherapy. The second group consisted of patients (30 eyes) who had an enhanced regimen using Santabrim® 2 times a day as a third drug. To analyze the hypotensive effect, the data of corneally compensated IOP were compared at the first visit and 1 month after the appointment or enhancement of the local hypotensive regimen. Safety was assessed by comparing the degree of fluorescein staining of the cornea, conjunctival hyperemia, OSDI questionnaire indicators and the level of adherence to treatment at the appropriate time in two groups of patients. Results . Santabrim® significantly reduces the level of IOP. The use of the drug as monotherapy allows to reduce IOP by 26.3 % of the initial level. Strengthening combination therapy by adding Santabrem® as a third drug allows reducing the level of IOP by an additional 15.9 %. Objective indicators of the condition of the tissues of the anterior surface of the eye have not changed significantly. Based on the results of the assessment of the main signs of dry eye syndrome (OSDI) and the degree of patient adherence to treatment, no significant changes were revealed. Conclusion . Brimonidine 0.1 % (Santabrim®) can be recommended for the hypotensive treatment of glaucoma both in monotherapy and in combination with other groups of local instillation drugs, and its direct neuroprotective effect additionally contributes to the stabilization of glaucoma opticoneuropathy.